PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the type 2 diabetes market will experience a shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class will occur; while dipeptidyl peptidase-4 inhibitors (DPP-4Is) will continue to grow, but at a much slower rate than previous years. GLP-1RAs and SGLT-2Is will experience the fastest growth of all classes at a CAGR of 12.2% and 13.0% respectively.

Scope

Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Although the T2D market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the T2D market?

The late-stage T2D pipeline is heavily populated with me-too drugs from the classes of GLP-1RAs, DPP-4Is, and SGLT-2Is. Despite this, an oral GLP-1RA formulation and an osmotic pump which delivers subcutaneous exenatide for one year at a time are expected to be game changers in the GLP-1RA class. Both are in Phase III clinical trials and are expected to increase compliance among T2D patients. Will the late-stage drugs make a significant impact on the T2D market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

The diagnosed prevalence of T2D in the world skyrocketed in the past 10 years and will continue increasing at the fast pace. How will epidemiological changes impact the growth of the future market?

Astellas Pharma
AstraZeneca
Biocon
Boehringer Ingelheim
Bristol-Myers Squibb
Chong Kun Dang
Chugai Pharmaceuticals
Daiichi Sankyo
Eli Lilly
GlaxoSmithKline
Intarcia Therapeutics
Johnson & Johnson
Kowa Company
LG Life Sciences
Merck & Co
Mitsubishi Tanabe
Novartis
Novo Nordisk
Pfizer
Roche
Sanofi
SatRx
Shenzhen Chipscreen Biosciences
Taisho Pharmaceuticals
Takeda

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

3Disease Overview

3.1Etiology

3.2Pathophysiology

3.3Prognosis

3.4Quality of Life

3.5Symptoms

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1US

4.3.25EU

4.3.3Japan

4.3.4China and India

4.4Forecast Methodology

4.4.1Sources Used for Diagnosed Prevalence of T2D

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods, Diagnosed Prevalent Cases of T2D

4.5Epidemiological Forecast for T2D (2015–2025)

4.5.1Diagnosed Prevalent Cases of T2D

4.5.2Age-Specific Diagnosed Prevalent Cases of T2D

4.5.3Sex-Specific Diagnosed Prevalent Cases of T2D

4.5.4Age-Standardized Diagnosed Prevalence of T2D

4.5.5Prevalent Cases of Chronic Kidney Disease Among Diagnosed T2D Cases

4.5.6Prevalent Cases of Cardiovascular Disease Among Diagnosed T2D Cases

4.5.7Prevalent Cases of Overweight/Obesity Among Diagnosed T2D Cases

4.5.8Prevalent Cases of Hypertension Among Diagnosed T2D Cases

4.5.9Prevalent Cases of Dyslipidemia Among Diagnosed T2D Cases

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Treatment Overview

5.1.1Diagnosis and Referrals

5.1.2Treatment Guidelines and Leading Prescribed Therapies

5.1.3Clinical Practice

5.2US

5.3France

5.4Germany

5.5Italy

5.6Spain

5.7UK

5.8Japan

5.9China

5.10India

6Competitive Assessment

6.1Overview

6.2Strategic Competitor Assessment

6.3Product Profiles – Major Brands

6.3.1Metformin

6.3.2Sulfonylureas and Other Insulin Secretagogues

6.3.3a-glucosidase Inhibitors

6.3.4Thiazolidinediones

6.3.5Glucagon-Like Peptide-1 Receptor Agonists

6.3.6Dipeptidyl-Peptidase 4 Inhibitors

6.3.7Sodium-Glucose Cotransporter 2 Inhibitors

6.3.8Insulin Formulations

7Unmet Needs and Opportunities

7.1Overview

7.2Disease-Modifying Treatments Providing Sustained Glycemic Control

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Drugs with Non-Glycemic Benefits

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Drugs with Improved Side-Effect Profiles

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Increased Patient Compliance

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Country

8.2.2Clinical Trials by Phase and Trial Status

8.3Promising Drugs in Clinical Development

8.3.1Semaglutide

8.3.2OG217SC/Semaglutide (oral)

8.3.3ITCA 650

8.3.4Marizev (omarigliptin)

8.3.5Ertugliflozin

8.3.6FIAsp

8.3.7Biosimilar Insulins

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Eli Lilly

9.3.2Novo Nordisk

9.3.3Sanofi

9.3.4GlaxoSmithKline

9.3.5AstraZeneca

9.3.6Merck & Co.

9.3.7Boehringer Ingelheim

9.3.8Takeda

9.3.9Roche

9.3.10Pfizer

9.3.11Johnson & Johnson

9.3.12Novartis

9.3.13Intarcia Therapeutics

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.3France

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Germany

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5Italy

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

10.6Spain

10.6.1Forecast

10.6.2Key Events

10.6.3Drivers and Barriers

10.7UK

10.7.1Forecast

10.7.2Key Events

10.7.3Drivers and Barriers

10.8Japan

10.8.1Forecast

10.8.2Key Events

10.8.3Drivers and Barriers

10.9China

10.9.1Forecast

10.9.2Key Events

10.9.3Drivers and Barriers

10.10India

10.10.1Forecast

10.10.2Key Events

10.10.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed T2D Patients

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiry Dates

11.4.5General Pricing Assumptions

11.4.6Individual Drug Assumptions

11.4.7Generic Erosion

11.4.8Pricing of Pipeline Agents

11.5Physicians and Specialists Included in this Study

11.6About the Authors

11.6.1Analyst – CVMD

11.6.2Director – CVMD

11.6.3Epidemiologist

11.6.4Global Director of Therapy Analysis and Epidemiology

11.6.5Global Head of Healthcare

11.7About GlobalData

11.8Contact Us

11.9Disclaimer

Table

Table 1: T2D Pathophysiology

Table 2: Symptoms of T2D

Table 3: Risk Factors and Comorbidities for T2D

Table 4: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D

Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D

Table 7: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D

Table 8: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D

Table 10: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages =20 Years, N, 2015–2025

Table 11: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015

Table 12: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages =20 Years, N (Row %), 2015

Table 13: Diagnostic Tests and Typical Criteria for T2D

Table 14: T2D Treatments

Table 15: Country Profile, T2D Management – US

Table 16: Country Profile, T2D Management – France

Table 17: Country Profile, T2D Management – Germany

Table 18: Country Profile, T2D Management – Italy

Table 19: Country Profile, T2D Management – Spain

Table 20: Country Profile, T2D Management – UK

Table 21: Country Profile, T2D Management – Japan

Table 22: Country Profile, T2D Management – China

Table 23: Country Profile, T2D Management – India

Table 24: Leading Branded Treatments for T2D, 2015

Table 25: Product Profile – Metformin

Table 26: Metformin SWOT Analysis, 2015

Table 27: Global Sales Forecasts ($M) for Metformin, 2015–2025

Table 28: First-Generation SUs

Table 29: Second-Generation SUs

Table 30: Product Profile – SUs

Table 31: SUs SWOT Analysis, 2015

Table 32: Global Sales Forecasts ($M) for SUs and non-SUs, 2015–2025

Table 33: Product Profile – Acarbose

Table 34: AGIs SWOT Analysis, 2015

Table 35: Global Sales Forecasts ($M) for AGIs, 2015–2025

Table 36: Product Profile – Actos

Table 37: TZDs SWOT Analysis, 2015

Table 38: Global Sales Forecasts ($M) for TZDs, 2015–2025

Table 39: GLP-1RAs

Table 40: Product Profile – Byetta

Table 41: Byetta SWOT Analysis, 2015

Table 42: Global Sales Forecasts ($M) for Byetta, 2015–2025

Table 43: Product Profile – Victoza

Table 44: Victoza SWOT Analysis, 2015

Table 45: Global Sales Forecasts ($M) for Victoza, 2015–2025

Table 46: Product Profile – Bydureon

Table 47: Bydureon SWOT Analysis, 2015

Table 48: Global Sales Forecasts ($M) for Bydureon, 2015–2025

Table 49: Product Profile – Lyxumia

Table 50: Lyxumia SWOT Analysis, 2015

Table 51: Global Sales Forecasts ($M) for Lyxumia, 2015–2025

Table 52: Product Profile – Tanzeum

Table 53: Tanzeum SWOT Analysis, 2015

Table 54: Global Sales Forecasts ($M) for Tanzeum, 2015–2025

Table 55: Product Profile – Trulicity

Table 56: Trulicity SWOT Analysis, 2015

Table 57: Global Sales Forecasts ($M) for Trulicity, 2015–2025

Table 58: Marketed DPP-4Is

Table 59: Marketed DPP-4Is in Combination with Other OADs

Table 60: Product Profile – Januvia

Table 61: Januvia SWOT Analysis, 2015

Table 62: Global Sales Forecasts ($M) for Januvia, Janumet, Janumet XR, 2015–2025

Table 63: Product Profile – Onglyza

Table 64: Onglyza SWOT Analysis, 2015

Table 65: Global Sales Forecasts ($M) for Onglyza, Kombiglyze, XR, 2015–2025

Table 66: Product Profile – Tradjenta

Table 67: Tradjenta SWOT Analysis, 2015

Table 68: Global Sales Forecasts ($M) for Tradjenta, Jentadueto, 2015–2025

Table 69: Product Profile – Galvus

Table 70: Galvus SWOT Analysis, 2015

Table 71: Global Sales Forecasts ($M) for Galvus, Eucreas, 2015–2025

Table 72: Product Profile – Nesina

Table 73: Nesina SWOT Analysis, 2015

Table 74: Global Sales Forecasts ($M) for Nesina, Oseni, Kazano, 2015–2025

Table 75: Product Profile – Tenelia

Table 76: Tenelia SWOT Analysis, 2015

Table 77: Global Sales Forecasts ($M) for Tenelia, 2015–2025

Table 78: Product Profile – Suiny

Table 79: Suiny SWOT Analysis, 2015

Table 80: Global Sales Forecasts ($M) for Suiny, 2015–2025

Table 81: Product Profile – Zafatek

Table 82: Zafatek SWOT Analysis, 2015

Table 83: Global Sales Forecasts ($M) for Zafatek, 2015–2025

Table 84: SGLT-2Is

Table 85: Marketed SGLT-2Is in Combination with Other T2D Drugs

Table 86: Product Profile – Forxiga

Table 87: Forxiga SWOT Analysis, 2015

Table 88: Global Sales Forecasts ($M) for Forxiga, Xigduo XR, SaxaDapa, SaxaDapa + metformin, 2015–2025

Table 89: Product Profile – Invokana

Table 90: Invokana SWOT Analysis, 2015

Table 91: Global Sales Forecasts ($M) for Invokana, InvokaMet, XR, IR, 2015–2025

Table 92: Product Profile – Jardiance

Table 93: Jardiance SWOT Analysis, 2015

Table 94: Global Sales Forecasts ($M) for Jardiance, Synjardy, Glyxambi, 2015–2025

Table 95: Product Profile – Apleway

Table 96: Apleway SWOT Analysis, 2015

Table 97: Global Sales Forecasts ($M) for Apleway, 2015–2025

Table 98: Product Profile – Suglat

Table 99: Suglat SWOT Analysis, 2015

Table 100: Global Sales Forecasts ($M) for Suglat, 2015–2025

Table 101: Product Profile – Lusefi

Table 102: Lusefi SWOT Analysis, 2015

Table 103: Global Sales Forecasts ($m) for Lusefi, 2015–2025

Table 104: Insulins – Overview and Comparison

Table 105: Insulin Formulations

Table 106: Product Profile – Humalog

Table 107: Humalog SWOT Analysis, 2015

Table 108: Global Sales Forecasts ($M) for Humalog, Humalog Mixes, Humalog 200U, 2015–2025

Table 109: Product Profile – Lantus

Table 110: Lantus SWOT Analysis, 2015

Table 111: Global Sales Forecasts ($M) for Lantus, Toujeo LixiLan, 2015–2025

Table 112: Toujeo SWOT Analysis, 2015

Table 113: Product Profile – Levemir

Table 114: Levemir SWOT Analysis, 2015

Table 115: Global Sales Forecasts ($M) for Levemir, 2015–2025

Table 116: Product Profile – NovoLog

Table 117: NovoLog SWOT Analysis, 2015

Table 118: Global Sales Forecasts ($M) for NovoRapid, NovoMix, FIAsp, 2015–2025

Table 119: Product Profile – Apidra

Table 120: Apidra SWOT Analysis, 2015

Table 121: Global Sales Forecasts ($M) for Apidra, 2015–2025

Table 122: Product Profile – Tresiba

Table 123: Tresiba SWOT Analysis, 2015

Table 124: Global Sales Forecasts ($M) for Tresiba, Xultophy, Ryzodeg, 2015–2025

Table 125: Product Profile – Afrezza

Table 126: Afrezza SWOT Analysis, 2015

Table 127: Global Sales Forecasts ($M) for Afrezza, 2015–2025

Table 128: Unmet Needs and Opportunities in T2D

Table 129: T2D – Clinical Trials by Phase and Status, 2015

Table 130: T2D – Phase Pipeline, 2015

Table 131: Comparison of Therapeutic Classes in Development for T2D, 2015

Table 132: Product Profile – Semaglutide

Table 133: Semaglutide SWOT Analysis, 2015

Table 134: Global Sales Forecasts ($M) for Semaglutide, 2015–2025

Table 135: Product Profile – OG217SC

Table 136: OG217SC SWOT Analysis, 2015

Table 137: Global Sales Forecasts ($M) for OG217SC, 2015–2025

Table 138: Product Profile – ITCA 650

Table 139: ITCA-650 SWOT Analysis, 2015

Table 140: Global Sales Forecasts ($M) for ITCA-650, 2015–2025

Table 141: Product Profile – Marizev

Table 142: Marizev SWOT Analysis, 2015

Table 143: Global Sales Forecasts ($M) for Marizev, 2015–2025

Table 144: Product Profile – Ertugliflozin

Table 145: Ertugliflozin SWOT Analysis, 2015

Table 146: Global Sales Forecasts ($M) for Ertugliflozin, Ertugliflozin + metformin, Sitagliptin + Ertugliflozin, 2015–2025

Table 147: Product Profile – FIAsp

Table 148: FIAsp SWOT Analysis, 2015

Table 149: Product Profile – Abasaglar

Table 150: Abasaglar SWOT Analysis, 2015

Table 151: Global Sales Forecasts ($M) for Abasaglar, 2015–2025

Table 152: Key Companies in the T2D Market, 2015

Table 153: Other Companies in the T2D Market, 2015

Table 154: Eli Lilly’s T2D Portfolio Assessment, 2015

Table 155: Eli Lilly SWOT Analysis, 2015

Table 156: Novo Nordisk’s T2D Portfolio Assessment, 2015

Table 157: Novo Nordisk SWOT Analysis, 2015

Table 158: Sanofi’s T2D Portfolio Assessment, 2015

Table 159: Sanofi SWOT Analysis, 2015

Table 160: GSK’s T2D Portfolio Assessment, 2015

Table 161: GSK SWOT Analysis, 2015

Table 162: AstraZeneca’s T2D Portfolio Assessment, 2015

Table 163: AstraZeneca SWOT Analysis, 2015

Table 164: Merck’s T2D Portfolio Assessment, 2015

Table 165: Merck SWOT Analysis, 2015

Table 166: BI’s T2D Portfolio Assessment, 2015

Table 167: BI SWOT Analysis, 2015

Table 168: Takeda’s T2D Portfolio Assessment, 2015

Table 169: Takeda SWOT Analysis, 2015

Table 170: Roche’s T2D Portfolio Assessment, 2015

Table 171: Roche SWOT Analysis, 2015

Table 172: Pfizer’s T2D Portfolio Assessment, 2015

Table 173: Pfizer SWOT Analysis, 2015

Table 174: J&J’s T2D Portfolio Assessment, 2015

Table 175: J&J SWOT Analysis, 2015

Table 176: Novartis’ T2D Portfolio Assessment, 2015

Table 177: Novartis SWOT Analysis, 2015

Table 178: Intarcia Therapeutics’ T2D Portfolio Assessment, 2015

Table 179: Intarcia Therapeutics SWOT Analysis, 2015

Table 180: Global Sales Forecasts ($M) for T2D, 2015–2025

Table 181: T2D Market – Drivers and Barriers, 2015

Table 182: Sales Forecasts ($M) for T2D in the US, 2015–2025

Table 183: Key Events Impacting Sales for T2D in the US, 2015–2025

Table 184: T2D Market – Drivers and Barriers in the US, 2015

Table 185: Sales Forecasts ($M) for T2D in France, 2015–2025

Table 186: Key Events Impacting Sales for T2D in France, 2015–2025

Table 187: T2D Market – Drivers and Barriers in France, 2015

Table 188: Sales Forecasts ($M) for T2D in Germany, 2015–2025

Table 189: Key Events Impacting Sales for T2D in Germany, 2015–2025

Table 190: T2D Market – Drivers and Barriers in Germany, 2015

Table 191: Sales Forecasts ($M) for T2D in Italy, 2015–2025

Table 192: Key Events Impacting Sales for T2D in Italy, 2015–2025

Table 193: T2D Market – Drivers and Barriers in Italy, 2015

Table 194: Sales Forecasts ($M) for T2D in Spain, 2015–2025

Table 195: Key Events Impacting Sales for T2D in Spain, 2015–2025

Table 196: T2D Market – Drivers and Barriers in Spain, 2015

Table 197: Sales Forecasts ($M) for T2D in the UK, 2015–2025

Table 198: Key Events Impacting Sales for T2D in the UK, 2015–2025

Table 199: T2D Market – Drivers and Barriers in the UK, 2015

Table 200: Sales Forecasts ($M) for T2D in Japan, 2015–2025

Table 201: Key Events Impacting Sales for T2D in Japan, 2015–2025

Table 202: T2D Market – Drivers and Barriers in Japan, 2015

Table 203: Sales Forecasts ($M) for T2D in China, 2015–2025

Table 204: Key Events Impacting Sales for T2D in China, 2015–2025

Table 205: T2D Market – Drivers and Barriers in China, 2015

Table 206: Sales Forecasts ($M) for T2D in India, 2015–2025

Table 207: Key Events Impacting Sales for T2D in India, 2015–2025

Table 208: T2D Market – Drivers and Barriers in India, 2015

Table 209: Key Launch Dates

Table 210: Key Patent Expiries

Table 211: Number of High-Prescribing Physicians Surveyed

Figures

Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages =20 Years, N, 2015–2025

Figure 2: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2015

Figure 3: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages =20 Years, N, 2015

Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of T2D (%), Ages =20 Years, by Sex, 2015

Figure 5: 9MM, Prevalent Cases of CKD Among Diagnosed T2D Cases, Both Sexes, Ages =20 Years, N, 2015

Figure 6: 8MM, Prevalent Cases of CVD Among Diagnosed T2D Cases, Both Sexes, Ages =20 Years, N, 2015

Figure 7: 9MM, Prevalent Cases of Overweight/Obesity Among Diagnosed T2D, Both Sexes, Ages =20 Years, N, 2015

Figure 8: 9MM, Prevalent Cases of Hypertension Among Diagnosed T2D, Both Sexes, Ages =20Years, N, 2015

Figure 9: 8MM, Prevalent Cases of Dyslipidemia Among Diagnosed T2D, Both Sexes, Ages =20 Years, N, 2015

Figure 10: Incretin and SGLT-2I Mechanisms of Action

Figure 11: ADA/EASD General Recommendations for Antihyperglycemic Therapy

Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2015–2025

Figure 13: Company Portfolio Gap Analysis in T2D, 2015–2025

Figure 14: 9MM, Global Sales for T2D by Region, 2015–2025

Figure 15: Sales for T2D in the US by Drug Class, 2015–2025

Figure 16: Sales for T2D in France by Drug Class, 2015–2025

Figure 17: Sales for T2D in Germany by Drug Class, 2015–2025

Figure 18: Sales for T2D in Italy by Drug Class, 2015–2025

Figure 19: Sales for T2D in Spain by Drug Class, 2015–2025

Figure 20: Sales for T2D in the UK by Drug Class, 2015–2025

Figure 21: Sales for T2D in Japan by Drug Class, 2015–2025

Figure 22: Sales for T2D in China by Drug Class, 2015–2025

Figure 23: Sales for T2D in India by Drug Class, 2015–2025

Frequently asked questions

PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025 in real time.

  • Access a live PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.